Nuvectis Pharma, Inc.
We are a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology. We are currently developing two preclinical drug candidates with the lead candidate expected to begin a Phase 1 clinical trial in the fourth quarter of 2021.
NXP800, one of our lead preclinical drug candidates, is an oral small molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway. The HSF1 signaling pathway plays an important role in the initiation and progression of many cancers. Our initial target indications for NXP800, advanced ovarian clear cell carcinoma (OCCC) and relapse/refractory endometrioid ovarian cancer, are both serious conditions of unmet medical need.
NXP900, our other lead preclinical drug candidate, is an oral small molecule SRC/YES1 kinase inhibitor. SRC is aberrantly activated in many cancer types, including solid tumors such as breast, colon, prostate, pancreatic and ovarian cancers, while remaining predominantly inactive in non-cancerous cells. SRC overactivation is generally associated with late-stage cancers, metastatic potential and resistance to therapies and poor clinical prognosis. NXP900 has demonstrated potent and selective target inhibition in vitro, and substantial tumor growth inhibition in relevant xenograft models. We plan to continue to advance NXP900 through the preclinical development stages to enable a first-in-human clinical study.
*Note: The net loss figure is for the nine months that ended Sept. 30, 2021.
(Note: Nuvectis Pharma upsized its IPO at pricing on Feb. 3, 2022, to 3.2 million shares, up from 2.08 million, and priced the IPO at $5 – the bottom of its $5-to-$7 range to raise $16 million. Previously: Nuvectis Pharma cut its IPO’s size by 57.2 percent in an S-1/A filing dated Jan. 18, 2022. The number of shares was cut to 2.08 million, down from 2.3 million shares initially, and the price range was slashed to $5.00 to $7.00 – down from $12 to $14 initially – to raise $12.8 million. The sole book-runner was changed to H.C. Wainwright & Co., from ThinkEquity. Nuvectis Pharma had postponed its IPO on Dec. 1, 2021, the day that it was expected to start trading on the NASDAQ.)
|Address||1 Bridge Plaza Suite 275 Fort Lee, NJ, 07024|
|Phone Number||(201) 614-3150|
|View Prospectus:||Nuvectis Pharma, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-10.63 mil (last 12 months)|
|Price range||$5.00 - $5.00|
|Est. $ Volume||$16.0 mil|
|Manager / Joint Managers||H.C. Wainwright & Co.|
|Expected To Trade:||2/4/2022|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|